Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KOD
KODIAK SCIENCES INC.
NASDAQ
$37.72
▼ DOWN 3.58% (-1.40)

KEY STATISTICS

Market Cap$2.36 B
52w High$47.84
52w Low$8.29
Dividend Yield—
Frequency—
P/E-9.05
Volume468.97K
Shares Out.62.58M

COMPANY

LEADERSHIP

Victor Perlroth
CHIEF EXECUTIVE
Victor Perlroth

COMPENSATION 2026

Salary$792,497
Stock Awards$0
Incentive Plan Pay$772,824
All Other Comp.$10,868
Total$2,499,221

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 4, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
141

PRICE TARGET

Target High$80.00
Target Low$56.00
Target Median$59.50
Target Consensus$63.75

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2022-02-23Forward5:1

PRICE

$37.72 ▼ DOWN 3.58% (−$1.40)
OVERLAYS
$37.50$38.25$39.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM37.72

About Kodiak Sciences Inc.

https://kodiak.com ↗

Kodiak Sciences Inc. is a Palo Alto-based biopharmaceutical company developing therapeutics like KSI-301 for retinal diseases such as AMD and diabetic macular edema, with several candidates in clinical and preclinical stages.

INDUSTRY

Biotechnology

A PRODUCT KODIAK SCIENCES INC. IS KNOWN FOR

Tarcocimab tedromer
Tarcocimab tedromer

Tarcocimab tedromer is Kodiak's investigational anti-VEGF biopolymer conjugate in late-stage trials for retinal diseases like diabetic retinopathy and AMD.

COMPETITORS

COMPETITOR
ABBV COMPARE
ALC COMPARE
EYPT COMPARE
NVS COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
125
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.52% · 1.6M
VTI
0.00% · 1.3M
XSU.TO
0.05% · 1.0M
SCHA
0.03% · 195.7K
FESM
0.11% · 183.3K
TMSL
0.12% · 93.7K
USVM
0.16% · 74.4K
LABU
0.36% · 58.0K
PRFZ
0.07% · 49.6K
XRSU.L
0.05% · 36.0K
HRTS
2.24% · 33.2K
DFAS
0.01% · 23.2K
GSSC
0.08% · 21.3K
RSSL
0.05% · 18.7K
BBSC
0.06% · 11.3K
BBC
0.69% · 9.2K
FSML
0.10% · 3.9K
RFLR
0.14% · 3.5K
BIB
0.08% · 2.2K
ETLZ.DE
0.03% · 2.0K
VETS
0.15% · 1.1K
JHMH
0.04% · 207
USUE.DE
0.00% · 154
RESM
0.07% · 114

INSTITUTIONAL OWNERSHIP

SHARES OWNED
75.99%
HOLDERS
257
TOP 12 OF 257 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
19.9M sh · $776.05M
Blackrock, Inc.
4.1M sh · $161.11M
Blackrock Inc.
3.8M sh · $9.04M
Price T Rowe Associates Inc /Md/
3.2M sh · $126.57M
Point72 Asset Management, L.P.
2.8M sh · $46.44M
State Street Corp
2.4M sh · $94.26M
Goldman Sachs Group Inc
2.3M sh · $90.23M
Vanguard Group Inc
2.3M sh · $64.68M
Braidwell LP
2.1M sh · $57.96M
Rtw Investments, LP
1.5M sh · $56.72M
Boxer Capital Management, LLC
1.5M sh · $57.57M
T. Rowe Price Investment Management, Inc.
1.5M sh · $57.55M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Chris Jacobs
Chris Jacobs
Sale (Full)
2022-11-08
 Christopher L. Jacobs
Christopher L. Jacobs
Sale (Full)
2022-11-08

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
BORGESON JOHN A.
Purchase · 66.5K shares
2026-07-15
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CHAIRMAN AND CEO
PERLROTH VICTOR
Purchase · 100.0K shares
2026-07-15
★
DIRECTOR
Yang Taiyin
Purchase · 17.7K shares
2026-06-30
★
DIRECTOR
Bancroft Charles A
Purchase · 17.7K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 1
EQUAL WEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY JP Morgan OVERWEIGHT Chardan Capital BUY UBS BUY Barclays EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
ANAB$56.28COMPARE
PHAT$9.18COMPARE
BBOT$8.74COMPARE
OCS$12.21COMPARE